[Primary hyperparathyroidism. An alternative to the surgery].

Area of Science:

• Endocrinology
• Nephrology
• Oncology

Background:

• Primary hyperparathyroidism involves parathyroid gland adenoma/hyperplasia, leading to hypercalcemia primarily from elevated parathormone (PTH) secretion.
• Surgery is the only definitive treatment, but it poses risks for some patients.
• Conventional medical therapies like hydration, diuretics, and oral bisphosphonates are often insufficient for managing hypercalcemia in high-risk or surgical-refusing patients.

Observation:

• This case study focuses on a patient with primary hyperparathyroidism and hypercalcemia secondary to an adenoma.
• The patient was not a candidate for surgery and did not respond adequately to conventional medical management.
• The patient received treatment with zoledronic acid and cinacalcet.

Findings:

• Zoledronic acid, a potent parenteral bisphosphonate, effectively reduces calcium levels.
• Cinacalcet, a calcimimetic agent, lowers parathormone (PTH) secretion, addressing the root cause of hypercalcemia.
• The combined use of zoledronic acid and cinacalcet provides a viable therapeutic strategy for managing hypercalcemia in select patients.

Implications:

• This approach expands treatment options for hypercalcemia in primary hyperparathyroidism beyond surgery.
• Zoledronic acid and cinacalcet represent important therapeutic agents for patients with contraindications to parathyroidectomy.
• Further research into the long-term efficacy and safety of this combination therapy is warranted.